Sarepta Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and thank you for joining Guggenheim's 3rd Healthcare Innovation Conference. I am Debjit, one of the therapeutic analysts, and my privilege to host Michael Severino, the CEO of Sarepta Therapeutics. Thank you so much for making time for us, Michael.
It's a pleasure. Happy to be here.
Let's start off on a high level. I think you probably accepted one of the most challenging positions in biotech. What made you decide to come to Sarepta at this juncture?
Well, I see the setup at Sarepta as unique in a number of ways. One, it's very rare, almost unheard of for biotech at our scale to be in the position that we're in, which is that we have a commercial business with a leadership position in an important condition like Duchenne that generates substantial revenue, but where we can use that revenue to drive a pipeline with the value that I believe exists in our pipeline, and do it on the basis of our own cash flows, do it without the need to raise equity. When I look at the commercial business, I think it has very real potential. Obviously, 2025 was a challenging year for us, but I believe we've done a lot to address the concerns that arose in 2025.
We've focused the indicated population to the ambulatory patients for ELEVIDYS, where benefit-risk, I think, is quite clear. We've introduced new data, long-term data, functional data, imaging data that I think support the presence of substantial benefit there. We're managing risk effectively, and I think that will be a durable business. Our PMO business is very robust. I think we can use that experience, use that cash flow, not only to deliver a lot of good to Duchenne patients, but to advance this really promising siRNA pipeline as well. It was that combination that led me to join over the course of the summer.
Got it. You just reported your third quarter. The exon skipping business looks really strong and sticky. Could you walk us through the assumptions? We have got competitive launches, at least for one of your exons, hopefully next year. Your business seems to be very sticky with over 90% of the patients being home dosed. How do you see that evolve once you have competitive launches?
I'll first start with the attributes of our product. All of our exon skipping therapies, but particularly exon 51, given that is what is likely to face competition in the coming year with the Dyne program under FDA review. That program, our product has been on the market for more than a decade now. It has a very well-understood safety profile and a very favorable overall safety profile. We also have extensive long-term evidence, so real-world evidence supporting its use, prolonged time to ambulation, reduced decline over time in things like pulmonary function and cardiac function and overall mortality, things that really matter to patients, to their families, to physicians. That whole body of evidence, in our mind, is what creates a lot of the stickiness of these therapies. Above and beyond that, we have tremendous experience navigating this commercial marketplace. We understand the reimbursement pathways.
Our access groups are very effective at ensuring coverage for patients who are qualified. We have robust patient support programs in place, at-home dosing, which is critically important for these patients. On the order of about 90% of patients participate in the in-home dosing program, which is a tremendous feature in terms of ensuring the high levels of adherence that we've been able to demonstrate. All of those things are what lead to the stickiness of these programs, and all of those things I think will support us well when competitive entrants come into the marketplace.
Given that 90% of these patients are home dosed with a caregiver, how often do they see a physician before they can contemplate switching to a different therapy?
Well, that's going to depend on the individual physician practice in their offices in terms of how frequently they see these patients, but it's typically going to be on a frequency of once a quarter or longer. But again, we view the visit to the physician not as the primary determinant of whether a patient stays on therapy or switches to a new therapy. It'll be what is their experience with that therapy? Have they been stable over a long period of time? Are they comfortable with the safety profile that they've observed and the benefit that they've derived? All these things are going to be part of the discussion between the patients, their families, and the physicians when they talk about what potentials exist in the marketplace.
Got it. Now, if you think about the exon 51 market, you have the new incident patients, you have patients who are probably already on ELEVIDYS, sorry, on EXONDYS, and the older non-ambulant patients who may or may not be on EXONDYS. Where do you think you're likely to gain or lose market share if Dyne is approved next year?
Well, again, I think that the stable patient base is going to be very sticky. I think that our product will do very well in the face of competition with those stable patients who have been on the therapy for, many of them, for an extended period of time, have experienced the benefit, and are very comfortable with the safety profile that they've observed. I think that's going to be a core part of our base. We'll compete for new patients based on the attributes of the products. For our product, the important features are going to be the ones I already mentioned. The time in the market, the well-understood safety profile, the data to support benefit-risk. That'll be our value proposition.
We'll have to see what the label looks like for Dyne, when their PDUFA date comes in terms of what they'll be able to say. But we feel good about what we have to offer to this patient population.
Got it. Moving to gene therapy and ELEVIDYS. Third quarter would, as the way, and if I understood correctly, this is kind of the new baseline in terms of patient starts. Do you expect to see this move higher as physicians now have a better understanding on how to manage these patients, especially post-therapy?
As we described on both the most recent quarterly call and the second quarter call before that, we feel like what we're observing now is a clean baseline. Given the six-month journey from start form to dosing, the demand that we're seeing now is the demand that was generated much earlier in the year, before our commercial sales force expansion was in place, before that sales force had the new data at their disposal, the three-year data from EMBARK, some of the imaging data in 8 to 12-year-old patients, which are critical in understanding benefit risk as patients progress in their journey with Duchenne. Now that's all in place, the data are in the hands of the field force, they're out having these discussions with physicians. Those conversations are going well, and from this point forward, we'll be able to assess the effectiveness of those conversations.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
